WHO is convening more than 300 scientists, who will review evidence on more than 25 families of viruses and bacteria, as well as “Disease X,” pointing to an unknown pathogen that could cause serious epidemics worldwide. bridge.
The progress began Friday and will guide global investment, research and development (R&D), particularly in vaccines, testing and treatments.
Necessary for quick response
The Priority Pathogens List was first published in 2017 and includes COVID-19, Ebola viral diseases, Lassa fever, Middle East respiratory syndrome (MERS), Severe Acute Respiratory Syndrome (SARS), Rift Valley fever, Zika and “Disease X”.
“Targeting the preferred pathogens and virus families for research and development of countermeasures is needed to respond to epidemics and pandemics quickly and effectively”, said Dr Michael Ryan, Executive Director of the WHO Health Emergencies Program.
“Without substantial R&D investment before COVID-19 pandemic, it will can not for a safe and effective vaccine to be developed in record time,” he added.
Research route
Experts will recommend the list of priority pathogens that need further research investment.
This process will include both science and public health criteria, as well as criteria related to socioeconomic impact, accessibility and equity.
R&D pathways will be developed for priority identified pathogens, given knowledge gaps and research areas.
Desired specifications for vaccines, treatments and diagnostic tests will also be determined, where relevant.
Efforts will also be made to map, compile and facilitate clinical trials to develop these tools.
The revised list is expected to be published in early 2023.
